Page 1

Migraine Market to Witness Huge Growth by 2023 The Report Global Migraine Market by Manufacturers, Countries, Type and Application, Forecast to 2023 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants.

Global Migraine Market Synopsis: This report studies the Global Migraine Market over the forecast period of 2019 to 2023. The Global Migraine Market is expected to grow at an impressive Compound Annual Growth Rate (CAGR) from 2019 to 2023. The Migraine Market is witnessing a shift in terms of strong R&D with the introduction of CGRP-based therapies and uptake of novel drug classes such as ditans, gepants, and reformulation of triptans for both chronic and episodic migraine. Get Sample Study Papers of “Global Migraine Market” @ https://www.businessindustryreports.com/sample-request/163005 . The Global “Migraine Market” research 2019 highlights the major details and provides in-depth analysis of the market along with the future growth, prospects and Industry demands analysis explores with the help of complete report with 50 Pages, figures, graphs and table of contents to analyze the situations of global Migraine Market and Assessment to 2023. Migraine is a debilitating neurological disease characterized by recurrent attacks of severe throbbing head pain that can last for more than three days. Migraine pain may get worse on movement, preventing the patient from carrying out normal, day-to-day activities. In about one-third of attacks, both sides of the head, face, or neck are affected.


The current migraine treatment landscape is mainly dominated by generic drugs, as the majority of migraine drugs have seen their patents expire. However current treatments leave a large number of patients undertreated; many of the drugs, for both acute and preventative treatment, have poor efficacy profiles which are ineffective in a large number of patients. In addition to this, many of these drugs are contraindicated in patients with certain co-morbidities. Current research focuses on using novel mechanisms of action such as CGRP-based receptor and ligand inhibition, corticotrophin receptor antagonism, and nitrous oxide inhibition. Approval of CGRP monoclonal antibodies is one of the key developments in the preventive market. Regionally, Rise in focus of vendors on the emerging markets, such as Asia-Pacific and LAMEA, is expected to boost the market growth. Asia-Pacific is projected to witness significant growth in future, owing to rise in demand for better healthcare facilities and improvements in healthcare infrastructure. Furthermore, this region presents remarkable opportunities for the venture capitalists and investors, as the developed markets are comparatively saturated. Major Players profiled in the Migraine Market report incorporate: Abbott Laboratories, Allergan Plc., AstraZeneca, Eisai Co., Ltd., Endo International Plc., GlaxoSmithKline Plc., Impax Laboratories, Johnson & Johnson, Merck & Co., and Pfizer Inc. Latest Industry News Allergan plc (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's New Drug Application (NDA) for ubrogepant for the acute treatment of migraine in adults. The NDA filing is based on the successful completion of four clinical trials – two pivotal studies, ACHIEVE I and ACHIEVE II, which demonstrated the efficacy, safety and tolerability of ubrogepant, as well as two additional safety studies. A 10-month review period has been assigned with the Prescription Drug User Fee Act (PDUFA) in the fourth quarter of 2019. "Following the acceptance and expected review of this NDA, we anticipate ubrogepant to be the first approved oral CGRP receptor antagonist for the acute treatment of migraine, and may be used in conjunction with other available migraine treatments," said David Nicholson, Chief Research and Development Officer, Allergan. "As a leader in Chronic Migraine research for more than 20 years, Allergan looks to provide options for patients who need new acute and preventative treatments for migraine. Request a Discount on standard prices of this premium report @ https://www.businessindustryreports.com/check-discount/163005 . Region segment: This report is segmented into several key regions, with sales, revenue, market share (%) and growth Rate (%) of Migraine in these regions, from 2014 to 2023 (forecast), covering: North America, Europe, Asia Pacific, Middle East & Africa and South America. Significant points in table of contents: Market Definition, Market Overview, Business Introduction, Segmentation (Region Level), Segmentation (Type Level), Segmentation (Industry Level), Segmentation


(Channel Level), Market Forecast Year, Segmentation Type, Segmentation Industry, Market Cost Analysis, and Conclusion. Report contents include 1 Analysis of the Migraine Market including revenues, future growth, market outlook 2 Historical data and forecast 3 Regional analysis including growth estimates 4 Analyzes the end user markets including growth estimates. 5 Profiles on Migraine including products, sales/revenues, and market position 6 Market structure, market drivers and restraints. About us BusinessindustryReports.com is digital database of comprehensive market reports for global industries. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined – we want to help our clients envisage their business environment so that they are able to make informed, strategic and therefore successful decisions for themselves. Media Contact Business Industry Reports Pune – India sales@businessindustryreports.com +19376349940

Profile for businessindustryreports10

Migraine market 2019  

The Report Global Migraine Market by Manufacturers, Countries, Type and Application, Forecast to 2023 provides information on pricing, marke...

Migraine market 2019  

The Report Global Migraine Market by Manufacturers, Countries, Type and Application, Forecast to 2023 provides information on pricing, marke...

Advertisement